DiaMedica Therapeutics (DMAC)
(Delayed Data from NSDQ)
$2.39 USD
-0.10 (-4.02%)
Updated Apr 19, 2024 04:00 PM ET
After-Market: $2.44 +0.05 (2.09%) 7:58 PM ET
2-Buy of 5 2
D Value D Growth D Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
DMAC 2.39 -0.10(-4.02%)
Will DMAC be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for DMAC based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for DMAC
DiaMedica (DMAC) Up as Stroke Study Dosing Begins Post Relaunch
DiaMedica Therapeutics (DMAC) Loses -19.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
DMAC: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Cardiol Therapeutics (CRDL) Stock Outpacing Its Medical Peers This Year?
Is DiaMedica Therapeutics (DMAC) Stock Outpacing Its Medical Peers This Year?
What Makes DiaMedica Therapeutics, Inc. (DMAC) a New Buy Stock
Other News for DMAC
Analysts Offer Insights on Healthcare Companies: Diamedica Therapeutics (DMAC), Inspire Medical Systems (INSP) and Maravai Lifesciences Holdings (MRVI)
DiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke
DiaMedica Therapeutics says first patient dosed in relaunch of DM199 trial
Diamedica Therapeutics Updates SEC Filing
DiaMedica Therapeutics price target lowered by $3 at Craig-Hallum, here's why